2014
DOI: 10.1002/pbc.25391
|View full text |Cite
|
Sign up to set email alerts
|

Low and fixed dose of hydroxyurea is effective and safe in patients with HbSβ+ thalassemia with IVS1‐5(G→C) mutation

Abstract: In view of easy affordability, better acceptability, minimal toxicity, the need of infrequent monitoring and its potential effectiveness, low and fixed dose of hydroxyurea is suitable for treatment of patients with HbSβ(+) -thalassemia in resource poor setting.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

3
20
0

Year Published

2015
2015
2020
2020

Publication Types

Select...
6
2

Relationship

0
8

Authors

Journals

citations
Cited by 19 publications
(23 citation statements)
references
References 40 publications
(58 reference statements)
3
20
0
Order By: Relevance
“…Significant decreases in LDH, TB, DB, and IB were seen among SCA-HU + patients, suggesting an improvement in the hemolytic profile. These findings are supported by results reported by Dehury et al, who also observed reduced levels of LDH and TB in association with HU use in HbS β + thalassemia [ 37 ].…”
Section: Discussionsupporting
confidence: 88%
“…Significant decreases in LDH, TB, DB, and IB were seen among SCA-HU + patients, suggesting an improvement in the hemolytic profile. These findings are supported by results reported by Dehury et al, who also observed reduced levels of LDH and TB in association with HU use in HbS β + thalassemia [ 37 ].…”
Section: Discussionsupporting
confidence: 88%
“…The use of hydroxyurea in SCA is especially attractive for low‐resource settings because of its ease of oral administration, potential for reducing medical cost, and safety profile . In the SCATE study, toxicities from hydroxyurea were uncommon and no different than reported in other pediatric populations (<10% severe neutropenia and reticulocytopenia) . Other adverse events during the study (neurological and non‐neurological) were also rare and not observed in any greater frequency than prior studies .…”
Section: Discussionmentioning
confidence: 81%
“…Currently, more than 200 causative molecular defects have been described so far in the β-globin gene causing β-thalassemia and also relation of some mutations have been found which respond to hydroxyurea 23 – 25 . Previously it was identified that the metabolite profile of β-thalassemia patients significantly differs from healthy 26 .…”
Section: Introductionmentioning
confidence: 99%